Back to Search
Start Over
COVID-19 Vaccination in Liver Cirrhosis: Safety and Immune and Clinical Responses
- Source :
- GE: Portuguese Journal of Gastroenterology, Pp 1-13 (2023)
- Publication Year :
- 2023
- Publisher :
- Karger Publishers, 2023.
-
Abstract
- Introduction: Three years after the beginning of the SARS-CoV-2 pandemic, the safety and efficacy of COVID-19 vaccination in liver cirrhosis (LC) patients remain controversial. We aimed to study the safety, immunological, and clinical responses of LC patients to COVID-19 vaccination. Methods: Prospective multicentric study in adults with LC eligible for COVID-19 vaccination, without prior known infection. Patients were followed up until the timing of a booster dose, SARS-CoV-2 infection, or death. Spike-protein immunoglobulin G antibody titers for SARS-CoV-2 at 2 weeks, 3 months, and 6 months postvaccination were assessed. Antibody titers 200 BAU/mL at 3 months. Conclusion: COVID-19 vaccines in patients with LC were safe, without serious adverse events. The humoral and clinical responses were similar to the reported for the general population. Humoral response was adversely impacted by older age and adenovirus vector vaccines and unrelated to the liver disease severity.
Details
- Language :
- English
- ISSN :
- 23871954
- Database :
- Directory of Open Access Journals
- Journal :
- GE: Portuguese Journal of Gastroenterology
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.9341cb7da8c34dc0a6f6cb01d12a868b
- Document Type :
- article
- Full Text :
- https://doi.org/10.1159/000534740